Unknown

Dataset Information

0

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.


ABSTRACT: Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL) 1 . Although a majority of patients will achieve a complete response following a single infusion of CD19-targeted CAR-modified T cells (CD19 CAR T cells)2-4, the broad applicability of this treatment is hampered by severe cytokine release syndrome (CRS), which is characterized by fever, hypotension and respiratory insufficiency associated with elevated serum cytokines, including interleukin-6 (IL-6)2,5. CRS usually occurs within days of T cell infusion at the peak of CAR T cell expansion. In ALL, it is most frequent and more severe in patients with high tumor burden2-4. CRS may respond to IL-6 receptor blockade but can require further treatment with high dose corticosteroids to curb potentially lethal severity2-9. Improved therapeutic and preventive treatments require a better understanding of CRS physiopathology, which has so far remained elusive. Here we report a murine model of CRS that develops within 2-3 d of CAR T cell infusion and that is potentially lethal and responsive to IL-6 receptor blockade. We show that its severity is mediated not by CAR T cell-derived cytokines, but by IL-6, IL-1 and nitric oxide (NO) produced by recipient macrophages, which enables new therapeutic interventions.

SUBMITTER: Giavridis T 

PROVIDER: S-EPMC6410714 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Giavridis Theodoros T   van der Stegen Sjoukje J C SJC   Eyquem Justin J   Hamieh Mohamad M   Piersigilli Alessandra A   Sadelain Michel M  

Nature medicine 20180528 6


Chimeric antigen receptor (CAR) therapy targeting CD19 is an effective treatment for refractory B cell malignancies, especially acute lymphoblastic leukemia (ALL) <sup>1</sup> . Although a majority of patients will achieve a complete response following a single infusion of CD19-targeted CAR-modified T cells (CD19 CAR T cells)<sup>2-4</sup>, the broad applicability of this treatment is hampered by severe cytokine release syndrome (CRS), which is characterized by fever, hypotension and respiratory  ...[more]

Similar Datasets

2018-05-28 | GSE111236 | GEO
| S-EPMC6581910 | biostudies-literature
| S-EPMC7151347 | biostudies-literature
| S-EPMC7780220 | biostudies-literature
2018-05-24 | E-MTAB-6505 | biostudies-arrayexpress
| S-EPMC5833070 | biostudies-literature
| S-EPMC6200371 | biostudies-literature
| S-EPMC5778792 | biostudies-literature
| S-EPMC7895329 | biostudies-literature
| S-EPMC7414980 | biostudies-literature